NDA 217628 · Carwin Pharm Assoc
Clotic
Clotrimazole · Otic · Azole Antifungal
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Sep 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Sep 26, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
127
31 Phase 3, 11 recruiting
FAERS reports
11,719
9,076 serious, 937 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2026.
CLOTIC is indicated for the treatment of fungal otitis externa (otomycosis) due to Aspergillus species and Candida species in patients 18 years of age and older. Limitations of Use CLOTIC has only been studied in patients with intact tympanic membranes. The use of CLOTIC is not recommended for the treatment of otomycosis in patients with perforated tympanic membranes. CLOTIC is an azole antifungal indicated for the treatment of fungal otitis externa (otomycosis) due to Aspergillus species and Candida species in patients 18 years of age and older. ( 1 ) Limitations of Use CLOTIC has only been studied in patients with intact tympanic membranes. The use of CLOTIC is not recommended for the treatment of otomycosis in patients with perforated tympanic membranes
Mechanism: Clotrimazole is an azole antifungal agent [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CLOTIC · CLOTRIMAZOLE 1% · SOLUTION/DROPS, OTIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clotrimazole" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm BirthPivotal-lookingNot yet recruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT06349122 · 1,794 participants (planned) · Start Oct 2026 · Primary completion Jun 2029
Drug: Azithromycin; Ceftriaxone and 3 more · For: Bacterial Vaginosis; Vaginal Dysbiosis; Premature Delivery
- Study of the Management of Vaginal Discharge in West African Using Single Dose TreatmentsPivotal-lookingCompleted
Université de SherbrookeAcademic, hospital or other
NCT00313131 · 1,524 participants · Start Jan 2004
Drug: tinidazole+fluconazole vs metronidazole+clotrimazole · For: Bacterial Vaginosis; Candidiasis; Vaginitis
Sites: Accra, Ghana; Kumasi, Ghana; Conakry, Guinea · 7 sites in all
- Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01580878 · 707 participants · Start Jan 2012 · Primary completion Aug 2012
Drug: Butenafine Hydrochloride Cream, 1%; Lotrimin Ultra® and 1 more · For: Tinea Pedis
- Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious VaginitisPivotal-lookingCompleted
Laboratoire Innotech InternationalIndustry
NCT02515656 · 661 participants · Start Sep 2015 · Primary completion Aug 2016
Drug: POLYGYNAX®; GYNODAKTARIN® and 1 more · For: Vaginitis
Sites: Prague, Czechia; Lyon, France; Belgrade, Serbia · 4 sites in all
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the ToenailPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01302119 · 604 participants · Start Feb 2011 · Primary completion Dec 31, 2012
Drug: AN2690 Topical Solution, 5%; Solution Vehicle · For: Onychomycosis of Toenails
Sites: Phoenix, Arizona; Novato, California; Oceanside, California · 32 sites in all
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the ToenailPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01270971 · 594 participants · Start Dec 1, 2010 · Primary completion Nov 30, 2012
Drug: AN2690 Topical Solution, 5%; Solution Vehicle · For: Onychomycosis of Toenails
Sites: Tucson, Arizona; Hot Springs, Arkansas; Burbank, California · 27 sites in all
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's FootPivotal-lookingTerminated
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT01110330 · 583 participants · Start Jul 2007 · Primary completion Oct 2008
Drug: Placebo cream; Ketoconazole 2% cream (formulation F012) (Nizoral) and 1 more · For: Tinea Pedis
Sites: Bydgoszcz, Poland; Lodz, Poland; Lublin, Poland · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,384
- nausea825
- macular degeneration812
- pain782
- off label use769
- headache754
- dyspnoea726
- fatigue660
- diarrhoea618
- pyrexia528
- malaise483
- rash478
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 84 |
| 2005 | 114 |
| 2006 | 135 |
| 2007 | 113 |
| 2008 | 122 |
| 2009 | 149 |
| 2010 | 169 |
| 2011 | 229 |
| 2012 | 342 |
| 2013 | 215 |
| 2014 | 296 |
| 2015 | 452 |
| 2016 | 629 |
| 2017 | 588 |
| 2018 | 786 |
| 2019 | 961 |
| 2020 | 863 |
| 2021 | 993 |
| 2022 | 931 |
| 2023 | 893 |
| 2024 | 1,008 |
| 2025 | 1,037 |
| 2026 | 609 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Management of Otomycosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Hussain S, Philteos J, Kim H, et al. · Otol Neurotol 2026 · Systematic Review, Meta-Analysis
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2013 · Systematic Review
- Candidiasis (oropharyngeal).
Pankhurst CL · BMJ Clin Evid 2012 · Systematic Review
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- Dermatophyte infections.
Clayton YM · Postgrad Med J 1979 · Clinical Trial, Comparative Study
- Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment.
Russo R, Superti F, Karadja E, et al. · Mycoses 2019 · Randomized Controlled Trial
Sponsor: Carwin Pharm Assoc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.